Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

  • ID: 3846558
  • Company Profile
  • 36 pages
  • Global Markets Direct
1 of 4
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Summary

‘Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- The report provides overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Snapshot

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Overview

Key Information

Key Facts

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Research and Development Overview

Key Therapeutic Areas

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products Glance

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Early Stage Pipeline Products

IND/CTA Filed Products/Combination Treatment Modalities

Preclinical Products/Combination Treatment Modalities

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products

Unknown Products/Combination Treatment Modalities

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Drug Profiles

aminolevulinic acid hydrochloride

Product Description

Mechanism of Action

R&D Progress

Hitenercept

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis

Product Description

Mechanism of Action

R&D Progress

T-0001

Product Description

Mechanism of Action

R&D Progress

vincristine sulfate

Product Description

Mechanism of Action

R&D Progress

bevacizumab biosimilar

Product Description

Mechanism of Action

R&D Progress

Fderceptin

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Target CD30 for Solid Tumor

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis

Product Description

Mechanism of Action

R&D Progress

paclitaxel

Product Description

Mechanism of Action

R&D Progress

etanercept biosimilar

Product Description

Mechanism of Action

R&D Progress

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Target

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Projects

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Nifeviroc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Information

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Facts

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase II, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase I, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Preclinical, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Subsidiaries 34List of Figures

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll